Preload Image
Preload Image
Report Store mobile icon
Global Structural Heart Disease Interventional Therapy Market Growth 2024-2030

Global Structural Heart Disease Interventional Therapy Market Growth 2024-2030

2024

Global Structural Heart Disease Interventional Therapy Market Growth 2024-2030

The global structural heart disease interventional therapy market is projected to grow from US$ 13.24 billion in 2024 to US$ 27.84 billion by 2030, driven by rising cardiovascular

Buy Now Get Free sample

Request new version

Request for updated version of the report at the same price

Order Now

The global structural heart disease interventional therapy market is experiencing significant growth as a result of advancements in minimally invasive procedures, improved diagnostic capabilities, and the increasing prevalence of cardiovascular diseases. Structural heart disease refers to a range of conditions affecting the heart's valves, walls, and blood vessels, which can lead to serious complications such as heart failure, stroke, and death if left untreated. Interventional therapies, which typically involve catheter-based procedures, offer patients less invasive options for the treatment of structural heart conditions, making them a preferred choice over traditional open-heart surgery. Key therapies in this market include transcatheter aortic valve replacement (TAVR), transcatheter mitral valve repair (TMVR), and percutaneous left atrial appendage closure (LAAC). These procedures provide high efficacy in treating heart valve diseases, such as aortic stenosis and mitral regurgitation, without the need for lengthy recovery periods associated with surgery. The growth of the market is also driven by factors such as an aging global population, the rising incidence of heart diseases, and the increasing awareness of available treatment options. Furthermore, innovations in medical devices, such as advanced catheter technologies, imaging systems, and patient monitoring tools, are enhancing the precision and safety of these procedures, leading to better clinical outcomes and improving the overall patient experience. With the global healthcare sector focusing on reducing treatment costs and improving patient access to care, interventional therapies for structural heart disease are gaining popularity as a cost-effective alternative to traditional surgical methods. As the market continues to expand, ongoing clinical research, improved device technologies, and expanded indications for treatment are expected to further drive the adoption of interventional therapies for structural heart disease.

According to Publisher, global Structural Heart Disease Interventional Therapy market size is projected to grow from US$ 13240 million in 2024 to US$ 27840 million in 2030; it is expected to grow at a CAGR of 11.2% from 2024 to 2030. North America is currently the largest market for structural heart disease interventional therapies, driven by the high prevalence of heart disease, advanced healthcare infrastructure, and the presence of key market players. The United States, in particular, is a dominant player in the market, with well-established healthcare systems, a high rate of cardiovascular disease diagnoses, and the adoption of cutting-edge medical technologies. The country also benefits from favorable reimbursement policies, which enable greater patient access to interventional therapies. Moreover, the presence of leading medical device manufacturers and extensive research and development activities contribute to the growth of the market in this region. Europe follows closely behind, with countries such as Germany, France, and the United Kingdom leading the market due to high healthcare standards, widespread use of interventional therapies, and increasing government investments in the healthcare sector. The adoption of transcatheter valve replacement therapies in European countries has been notably high, driven by the region’s aging population and advancements in medical devices that improve procedural outcomes. The Asia-Pacific region is expected to witness rapid growth in the structural heart disease interventional therapy market, particularly in countries like Japan, China, and India. The growing awareness of heart disease, improving healthcare infrastructure, and a rising incidence of structural heart conditions in these countries are contributing to the increasing demand for interventional therapies. Additionally, the expanding availability of advanced medical technologies and favorable government policies aimed at improving healthcare access in emerging economies will support the market's expansion. In contrast, Latin America and the Middle East & Africa (MEA) are expected to experience moderate growth in the market, driven by improving healthcare systems and an increasing focus on addressing cardiovascular diseases in these regions. However, the adoption of interventional therapies in these regions may be slower due to limited healthcare budgets and lower awareness levels among the population.

What's Inside a Bonafide Research`s industry report?

A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.

Download Sample


The global structural heart disease interventional therapy market is segmented by therapy type, with major segments including transcatheter aortic valve replacement (TAVR), transcatheter mitral valve repair (TMVR), percutaneous left atrial appendage closure (LAAC), and others. Among these, transcatheter aortic valve replacement (TAVR) holds the largest market share, as it is widely used to treat aortic stenosis, a condition where the aortic valve becomes narrowed, impeding blood flow from the heart to the rest of the body. TAVR offers a minimally invasive alternative to traditional open-heart surgery and has proven to be highly effective in improving patient outcomes. The procedure involves the insertion of a catheter through a blood vessel to replace the damaged aortic valve with a prosthetic one. The success of TAVR in improving the quality of life and survival rates in patients with aortic stenosis has led to its growing adoption across various regions. Transcatheter mitral valve repair (TMVR) is another significant segment in the market, primarily used to treat mitral regurgitation, a condition where the mitral valve does not close properly, causing blood to flow backward into the heart. TMVR procedures, such as the MitraClip, are less invasive alternatives to traditional mitral valve surgery, offering patients faster recovery times and reduced risk of complications. Percutaneous left atrial appendage closure (LAAC) is also gaining popularity, particularly in patients with atrial fibrillation who are at risk for stroke. LAAC involves the closure of the left atrial appendage, where blood clots tend to form, thereby reducing the risk of stroke. Other therapy types, such as percutaneous valve repair and transcatheter pulmonary valve implantation (TPVI), also play a role in treating specific structural heart conditions, further expanding the market. As the development of new and improved therapies continues, the market for structural heart disease interventional therapies is expected to evolve, with novel treatments offering enhanced clinical outcomes and greater patient satisfaction.

The structural heart disease interventional therapy market is also segmented by application, with key areas of focus including aortic valve disease, mitral valve disease, left atrial appendage closure, and others. Aortic valve disease is one of the leading contributors to the market, with conditions such as aortic stenosis and aortic insufficiency requiring intervention through therapies like TAVR. The growing prevalence of aortic valve diseases, particularly among the aging population, is driving the demand for transcatheter therapies in this segment. Mitral valve disease, particularly mitral regurgitation, is another significant application area, with increasing adoption of TMVR procedures offering a less invasive treatment option compared to traditional valve surgery. The growing recognition of the benefits of minimally invasive mitral valve repair procedures is expanding the market in this segment. Left atrial appendage closure is increasingly being used for patients with atrial fibrillation who are at risk of stroke due to the formation of blood clots in the left atrial appendage. With the rising prevalence of atrial fibrillation globally, the demand for LAAC therapies is growing, particularly in regions with high rates of cardiovascular disease. Other applications in the market include pulmonary valve disease and patent foramen ovale (PFO) closure, where transcatheter procedures offer effective treatments for conditions that traditionally required more invasive surgeries. As interventional therapies continue to improve and expand to treat a wider range of structural heart diseases, the market for these therapies is expected to continue growing. Additionally, ongoing research into novel treatment options and the development of next-generation medical devices will likely drive further adoption across various segments of the market, ensuring the continued success and expansion of structural heart disease interventional therapies globally.


Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Sikandar Kesari

Sikandar Kesari

Research Analyst



Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Sikandar Kesari

Table of Contents

  • 1 Scope of the Report
  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered
  • 1.8 Market Estimation Caveats
  • 2 Executive Summary
  • 2.1 World Market Overview
  • 2.1.1 Global Structural Heart Disease Interventional Therapy Annual Sales 2019-2030
  • 2.1.2 World Current & Future Analysis for Structural Heart Disease Interventional Therapy by Geographic Region, 2019, 2023 & 2030
  • 2.1.3 World Current & Future Analysis for Structural Heart Disease Interventional Therapy by Country/Region, 2019, 2023 & 2030
  • 2.2 Structural Heart Disease Interventional Therapy Segment by Type
  • 2.2.1 Equipment
  • 2.2.2 Consumables
  • 2.3 Structural Heart Disease Interventional Therapy Sales by Type
  • 2.3.1 Global Structural Heart Disease Interventional Therapy Sales Market Share by Type (2019-2024)
  • 2.3.2 Global Structural Heart Disease Interventional Therapy Revenue and Market Share by Type (2019-2024)
  • 2.3.3 Global Structural Heart Disease Interventional Therapy Sale Price by Type (2019-2024)
  • 2.4 Structural Heart Disease Interventional Therapy Segment by Application
  • 2.4.1 Hospital
  • 2.4.2 Clinic
  • 2.4.3 Others
  • 2.5 Structural Heart Disease Interventional Therapy Sales by Application
  • 2.5.1 Global Structural Heart Disease Interventional Therapy Sale Market Share by Application (2019-2024)
  • 2.5.2 Global Structural Heart Disease Interventional Therapy Revenue and Market Share by Application (2019-2024)
  • 2.5.3 Global Structural Heart Disease Interventional Therapy Sale Price by Application (2019-2024)
  • 3 Global Structural Heart Disease Interventional Therapy by Company
  • 3.1 Global Structural Heart Disease Interventional Therapy Breakdown Data by Company
  • 3.1.1 Global Structural Heart Disease Interventional Therapy Annual Sales by Company (2019-2024)
  • 3.1.2 Global Structural Heart Disease Interventional Therapy Sales Market Share by Company (2019-2024)
  • 3.2 Global Structural Heart Disease Interventional Therapy Annual Revenue by Company (2019-2024)
  • 3.2.1 Global Structural Heart Disease Interventional Therapy Revenue by Company (2019-2024)
  • 3.2.2 Global Structural Heart Disease Interventional Therapy Revenue Market Share by Company (2019-2024)
  • 3.3 Global Structural Heart Disease Interventional Therapy Sale Price by Company
  • 3.4 Key Manufacturers Structural Heart Disease Interventional Therapy Producing Area Distribution, Sales Area, Product Type
  • 3.4.1 Key Manufacturers Structural Heart Disease Interventional Therapy Product Location Distribution
  • 3.4.2 Players Structural Heart Disease Interventional Therapy Products Offered
  • 3.5 Market Concentration Rate Analysis
  • 3.5.1 Competition Landscape Analysis
  • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
  • 3.6 New Products and Potential Entrants
  • 3.7 Mergers & Acquisitions, Expansion
  • 4 World Historic Review for Structural Heart Disease Interventional Therapy by Geographic Region
  • 4.1 World Historic Structural Heart Disease Interventional Therapy Market Size by Geographic Region (2019-2024)
  • 4.1.1 Global Structural Heart Disease Interventional Therapy Annual Sales by Geographic Region (2019-2024)
  • 4.1.2 Global Structural Heart Disease Interventional Therapy Annual Revenue by Geographic Region (2019-2024)
  • 4.2 World Historic Structural Heart Disease Interventional Therapy Market Size by Country/Region (2019-2024)
  • 4.2.1 Global Structural Heart Disease Interventional Therapy Annual Sales by Country/Region (2019-2024)
  • 4.2.2 Global Structural Heart Disease Interventional Therapy Annual Revenue by Country/Region (2019-2024)
  • 4.3 Americas Structural Heart Disease Interventional Therapy Sales Growth
  • 4.4 APAC Structural Heart Disease Interventional Therapy Sales Growth
  • 4.5 Europe Structural Heart Disease Interventional Therapy Sales Growth
  • 4.6 Middle East & Africa Structural Heart Disease Interventional Therapy Sales Growth
  • 5 Americas
  • 5.1 Americas Structural Heart Disease Interventional Therapy Sales by Country
  • 5.1.1 Americas Structural Heart Disease Interventional Therapy Sales by Country (2019-2024)
  • 5.1.2 Americas Structural Heart Disease Interventional Therapy Revenue by Country (2019-2024)
  • 5.2 Americas Structural Heart Disease Interventional Therapy Sales by Type
  • 5.3 Americas Structural Heart Disease Interventional Therapy Sales by Application
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil
  • 6 APAC
  • 6.1 APAC Structural Heart Disease Interventional Therapy Sales by Region
  • 6.1.1 APAC Structural Heart Disease Interventional Therapy Sales by Region (2019-2024)
  • 6.1.2 APAC Structural Heart Disease Interventional Therapy Revenue by Region (2019-2024)
  • 6.2 APAC Structural Heart Disease Interventional Therapy Sales by Type
  • 6.3 APAC Structural Heart Disease Interventional Therapy Sales by Application
  • 6.4 China
  • 6.5 Japan
  • 6.6 South Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia
  • 6.10 China Taiwan
  • 7 Europe
  • 7.1 Europe Structural Heart Disease Interventional Therapy by Country
  • 7.1.1 Europe Structural Heart Disease Interventional Therapy Sales by Country (2019-2024)
  • 7.1.2 Europe Structural Heart Disease Interventional Therapy Revenue by Country (2019-2024)
  • 7.2 Europe Structural Heart Disease Interventional Therapy Sales by Type
  • 7.3 Europe Structural Heart Disease Interventional Therapy Sales by Application
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia
  • 8 Middle East & Africa
  • 8.1 Middle East & Africa Structural Heart Disease Interventional Therapy by Country
  • 8.1.1 Middle East & Africa Structural Heart Disease Interventional Therapy Sales by Country (2019-2024)
  • 8.1.2 Middle East & Africa Structural Heart Disease Interventional Therapy Revenue by Country (2019-2024)
  • 8.2 Middle East & Africa Structural Heart Disease Interventional Therapy Sales by Type
  • 8.3 Middle East & Africa Structural Heart Disease Interventional Therapy Sales by Application
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries
  • 9 Market Drivers, Challenges and Trends
  • 9.1 Market Drivers & Growth Opportunities
  • 9.2 Market Challenges & Risks
  • 9.3 Industry Trends
  • 10 Manufacturing Cost Structure Analysis
  • 10.1 Raw Material and Suppliers
  • 10.2 Manufacturing Cost Structure Analysis of Structural Heart Disease Interventional Therapy
  • 10.3 Manufacturing Process Analysis of Structural Heart Disease Interventional Therapy
  • 10.4 Industry Chain Structure of Structural Heart Disease Interventional Therapy
  • 11 Marketing, Distributors and Customer
  • 11.1 Sales Channel
  • 11.1.1 Direct Channels
  • 11.1.2 Indirect Channels
  • 11.2 Structural Heart Disease Interventional Therapy Distributors
  • 11.3 Structural Heart Disease Interventional Therapy Customer
  • 12 World Forecast Review for Structural Heart Disease Interventional Therapy by Geographic Region
  • 12.1 Global Structural Heart Disease Interventional Therapy Market Size Forecast by Region
  • 12.1.1 Global Structural Heart Disease Interventional Therapy Forecast by Region (2025-2030)
  • 12.1.2 Global Structural Heart Disease Interventional Therapy Annual Revenue Forecast by Region (2025-2030)
  • 12.2 Americas Forecast by Country
  • 12.3 APAC Forecast by Region
  • 12.4 Europe Forecast by Country
  • 12.5 Middle East & Africa Forecast by Country
  • 12.6 Global Structural Heart Disease Interventional Therapy Forecast by Type
  • 12.7 Global Structural Heart Disease Interventional Therapy Forecast by Application
  • 13 Key Players Analysis
  • 13.1 Abbott Structural Heart
  • 13.1.1 Abbott Structural Heart Company Information
  • 13.1.2 Abbott Structural Heart Structural Heart Disease Interventional Therapy Product Portfolios and Specifications
  • 13.1.3 Abbott Structural Heart Structural Heart Disease Interventional Therapy Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.1.4 Abbott Structural Heart Main Business Overview
  • 13.1.5 Abbott Structural Heart Latest Developments
  • 13.2 philips
  • 13.2.1 philips Company Information
  • 13.2.2 philips Structural Heart Disease Interventional Therapy Product Portfolios and Specifications
  • 13.2.3 philips Structural Heart Disease Interventional Therapy Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.2.4 philips Main Business Overview
  • 13.2.5 philips Latest Developments
  • 13.3 Japen Lifeline
  • 13.3.1 Japen Lifeline Company Information
  • 13.3.2 Japen Lifeline Structural Heart Disease Interventional Therapy Product Portfolios and Specifications
  • 13.3.3 Japen Lifeline Structural Heart Disease Interventional Therapy Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.3.4 Japen Lifeline Main Business Overview
  • 13.3.5 Japen Lifeline Latest Developments
  • 13.4 Neovasc
  • 13.4.1 Neovasc Company Information
  • 13.4.2 Neovasc Structural Heart Disease Interventional Therapy Product Portfolios and Specifications
  • 13.4.3 Neovasc Structural Heart Disease Interventional Therapy Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.4.4 Neovasc Main Business Overview
  • 13.4.5 Neovasc Latest Developments
  • 13.5 Append Medical
  • 13.5.1 Append Medical Company Information
  • 13.5.2 Append Medical Structural Heart Disease Interventional Therapy Product Portfolios and Specifications
  • 13.5.3 Append Medical Structural Heart Disease Interventional Therapy Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.5.4 Append Medical Main Business Overview
  • 13.5.5 Append Medical Latest Developments
  • 13.6 Transverse Medical
  • 13.6.1 Transverse Medical Company Information
  • 13.6.2 Transverse Medical Structural Heart Disease Interventional Therapy Product Portfolios and Specifications
  • 13.6.3 Transverse Medical Structural Heart Disease Interventional Therapy Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.6.4 Transverse Medical Main Business Overview
  • 13.6.5 Transverse Medical Latest Developments
  • 13.7 Cardiomech
  • 13.7.1 Cardiomech Company Information
  • 13.7.2 Cardiomech Structural Heart Disease Interventional Therapy Product Portfolios and Specifications
  • 13.7.3 Cardiomech Structural Heart Disease Interventional Therapy Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.7.4 Cardiomech Main Business Overview
  • 13.7.5 Cardiomech Latest Developments
  • 13.8 Thubrikar Aortic Valve Inc.
  • 13.8.1 Thubrikar Aortic Valve Inc. Company Information
  • 13.8.2 Thubrikar Aortic Valve Inc. Structural Heart Disease Interventional Therapy Product Portfolios and Specifications
  • 13.8.3 Thubrikar Aortic Valve Inc. Structural Heart Disease Interventional Therapy Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.8.4 Thubrikar Aortic Valve Inc. Main Business Overview
  • 13.8.5 Thubrikar Aortic Valve Inc. Latest Developments
  • 13.9 boston scientific
  • 13.9.1 boston scientific Company Information
  • 13.9.2 boston scientific Structural Heart Disease Interventional Therapy Product Portfolios and Specifications
  • 13.9.3 boston scientific Structural Heart Disease Interventional Therapy Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.9.4 boston scientific Main Business Overview
  • 13.9.5 boston scientific Latest Developments
  • 13.10 Edwards Lifesciences Corporation
  • 13.10.1 Edwards Lifesciences Corporation Company Information
  • 13.10.2 Edwards Lifesciences Corporation Structural Heart Disease Interventional Therapy Product Portfolios and Specifications
  • 13.10.3 Edwards Lifesciences Corporation Structural Heart Disease Interventional Therapy Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.10.4 Edwards Lifesciences Corporation Main Business Overview
  • 13.10.5 Edwards Lifesciences Corporation Latest Developments
  • 13.11 Biomerics
  • 13.11.1 Biomerics Company Information
  • 13.11.2 Biomerics Structural Heart Disease Interventional Therapy Product Portfolios and Specifications
  • 13.11.3 Biomerics Structural Heart Disease Interventional Therapy Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.11.4 Biomerics Main Business Overview
  • 13.11.5 Biomerics Latest Developments
  • 13.12 LivaNova PLC
  • 13.12.1 LivaNova PLC Company Information
  • 13.12.2 LivaNova PLC Structural Heart Disease Interventional Therapy Product Portfolios and Specifications
  • 13.12.3 LivaNova PLC Structural Heart Disease Interventional Therapy Sales, Revenue, Price and Gross Margin (2019-2024)
  • 13.12.4 LivaNova PLC Main Business Overview
  • 13.12.5 LivaNova PLC Latest Developments
  • 14 Research Findings and Conclusion


Table 1. Structural Heart Disease Interventional Therapy Annual Sales CAGR by Geographic Region (2019, 2023 & 2030) & ($ millions)
Table 2. Structural Heart Disease Interventional Therapy Annual Sales CAGR by Country/Region (2019, 2023 & 2030) & ($ millions)
Table 3. Major Players of Equipment
Table 4. Major Players of Consumables
Table 5. Global Structural Heart Disease Interventional Therapy Sales by Type (2019-2024) & (K Units)
Table 6. Global Structural Heart Disease Interventional Therapy Sales Market Share by Type (2019-2024)
Table 7. Global Structural Heart Disease Interventional Therapy Revenue by Type (2019-2024) & ($ million)
Table 8. Global Structural Heart Disease Interventional Therapy Revenue Market Share by Type (2019-2024)
Table 9. Global Structural Heart Disease Interventional Therapy Sale Price by Type (2019-2024) & (US$/Unit)
Table 10. Global Structural Heart Disease Interventional Therapy Sales by Application (2019-2024) & (K Units)
Table 11. Global Structural Heart Disease Interventional Therapy Sales Market Share by Application (2019-2024)
Table 12. Global Structural Heart Disease Interventional Therapy Revenue by Application (2019-2024)
Table 13. Global Structural Heart Disease Interventional Therapy Revenue Market Share by Application (2019-2024)
Table 14. Global Structural Heart Disease Interventional Therapy Sale Price by Application (2019-2024) & (US$/Unit)
Table 15. Global Structural Heart Disease Interventional Therapy Sales by Company (2019-2024) & (K Units)
Table 16. Global Structural Heart Disease Interventional Therapy Sales Market Share by Company (2019-2024)
Table 17. Global Structural Heart Disease Interventional Therapy Revenue by Company (2019-2024) ($ Millions)
Table 18. Global Structural Heart Disease Interventional Therapy Revenue Market Share by Company (2019-2024)
Table 19. Global Structural Heart Disease Interventional Therapy Sale Price by Company (2019-2024) & (US$/Unit)
Table 20. Key Manufacturers Structural Heart Disease Interventional Therapy Producing Area Distribution and Sales Area
Table 21. Players Structural Heart Disease Interventional Therapy Products Offered
Table 22. Structural Heart Disease Interventional Therapy Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
Table 23. New Products and Potential Entrants
Table 24. Mergers & Acquisitions, Expansion
Table 25. Global Structural Heart Disease Interventional Therapy Sales by Geographic Region (2019-2024) & (K Units)
Table 26. Global Structural Heart Disease Interventional Therapy Sales Market Share Geographic Region (2019-2024)
Table 27. Global Structural Heart Disease Interventional Therapy Revenue by Geographic Region (2019-2024) & ($ millions)
Table 28. Global Structural Heart Disease Interventional Therapy Revenue Market Share by Geographic Region (2019-2024)
Table 29. Global Structural Heart Disease Interventional Therapy Sales by Country/Region (2019-2024) & (K Units)
Table 30. Global Structural Heart Disease Interventional Therapy Sales Market Share by Country/Region (2019-2024)
Table 31. Global Structural Heart Disease Interventional Therapy Revenue by Country/Region (2019-2024) & ($ millions)
Table 32. Global Structural Heart Disease Interventional Therapy Revenue Market Share by Country/Region (2019-2024)
Table 33. Americas Structural Heart Disease Interventional Therapy Sales by Country (2019-2024) & (K Units)
Table 34. Americas Structural Heart Disease Interventional Therapy Sales Market Share by Country (2019-2024)
Table 35. Americas Structural Heart Disease Interventional Therapy Revenue by Country (2019-2024) & ($ Millions)
Table 36. Americas Structural Heart Disease Interventional Therapy Revenue Market Share by Country (2019-2024)
Table 37. Americas Structural Heart Disease Interventional Therapy Sales by Type (2019-2024) & (K Units)
Table 38. Americas Structural Heart Disease Interventional Therapy Sales by Application (2019-2024) & (K Units)
Table 39. APAC Structural Heart Disease Interventional Therapy Sales by Region (2019-2024) & (K Units)
Table 40. APAC Structural Heart Disease Interventional Therapy Sales Market Share by Region (2019-2024)
Table 41. APAC Structural Heart Disease Interventional Therapy Revenue by Region (2019-2024) & ($ Millions)
Table 42. APAC Structural Heart Disease Interventional Therapy Revenue Market Share by Region (2019-2024)
Table 43. APAC Structural Heart Disease Interventional Therapy Sales by Type (2019-2024) & (K Units)
Table 44. APAC Structural Heart Disease Interventional Therapy Sales by Application (2019-2024) & (K Units)
Table 45. Europe Structural Heart Disease Interventional Therapy Sales by Country (2019-2024) & (K Units)
Table 46. Europe Structural Heart Disease Interventional Therapy Sales Market Share by Country (2019-2024)
Table 47. Europe Structural Heart Disease Interventional Therapy Revenue by Country (2019-2024) & ($ Millions)
Table 48. Europe Structural Heart Disease Interventional Therapy Revenue Market Share by Country (2019-2024)
Table 49. Europe Structural Heart Disease Interventional Therapy Sales by Type (2019-2024) & (K Units)
Table 50. Europe Structural Heart Disease Interventional Therapy Sales by Application (2019-2024) & (K Units)
Table 51. Middle East & Africa Structural Heart Disease Interventional Therapy Sales by Country (2019-2024) & (K Units)
Table 52. Middle East & Africa Structural Heart Disease Interventional Therapy Sales Market Share by Country (2019-2024)
Table 53. Middle East & Africa Structural Heart Disease Interventional Therapy Revenue by Country (2019-2024) & ($ Millions)
Table 54. Middle East & Africa Structural Heart Disease Interventional Therapy Revenue Market Share by Country (2019-2024)
Table 55. Middle East & Africa Structural Heart Disease Interventional Therapy Sales by Type (2019-2024) & (K Units)
Table 56. Middle East & Africa Structural Heart Disease Interventional Therapy Sales by Application (2019-2024) & (K Units)
Table 57. Key Market Drivers & Growth Opportunities of Structural Heart Disease Interventional Therapy
Table 58. Key Market Challenges & Risks of Structural Heart Disease Interventional Therapy
Table 59. Key Industry Trends of Structural Heart Disease Interventional Therapy
Table 60. Structural Heart Disease Interventional Therapy Raw Material
Table 61. Key Suppliers of Raw Materials
Table 62. Structural Heart Disease Interventional Therapy Distributors List
Table 63. Structural Heart Disease Interventional Therapy Customer List
Table 64. Global Structural Heart Disease Interventional Therapy Sales Forecast by Region (2025-2030) & (K Units)
Table 65. Global Structural Heart Disease Interventional Therapy Revenue Forecast by Region (2025-2030) & ($ millions)
Table 66. Americas Structural Heart Disease Interventional Therapy Sales Forecast by Country (2025-2030) & (K Units)
Table 67. Americas Structural Heart Disease Interventional Therapy Revenue Forecast by Country (2025-2030) & ($ millions)
Table 68. APAC Structural Heart Disease Interventional Therapy Sales Forecast by Region (2025-2030) & (K Units)
Table 69. APAC Structural Heart Disease Interventional Therapy Revenue Forecast by Region (2025-2030) & ($ millions)
Table 70. Europe Structural Heart Disease Interventional Therapy Sales Forecast by Country (2025-2030) & (K Units)
Table 71. Europe Structural Heart Disease Interventional Therapy Revenue Forecast by Country (2025-2030) & ($ millions)
Table 72. Middle East & Africa Structural Heart Disease Interventional Therapy Sales Forecast by Country (2025-2030) & (K Units)
Table 73. Middle East & Africa Structural Heart Disease Interventional Therapy Revenue Forecast by Country (2025-2030) & ($ millions)
Table 74. Global Structural Heart Disease Interventional Therapy Sales Forecast by Type (2025-2030) & (K Units)
Table 75. Global Structural Heart Disease Interventional Therapy Revenue Forecast by Type (2025-2030) & ($ Millions)
Table 76. Global Structural Heart Disease Interventional Therapy Sales Forecast by Application (2025-2030) & (K Units)
Table 77. Global Structural Heart Disease Interventional Therapy Revenue Forecast by Application (2025-2030) & ($ Millions)
Table 78. Abbott Structural Heart Basic Information, Structural Heart Disease Interventional Therapy Manufacturing Base, Sales Area and Its Competitors
Table 79. Abbott Structural Heart Structural Heart Disease Interventional Therapy Product Portfolios and Specifications
Table 80. Abbott Structural Heart Structural Heart Disease Interventional Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 81. Abbott Structural Heart Main Business
Table 82. Abbott Structural Heart Latest Developments
Table 83. philips Basic Information, Structural Heart Disease Interventional Therapy Manufacturing Base, Sales Area and Its Competitors
Table 84. philips Structural Heart Disease Interventional Therapy Product Portfolios and Specifications
Table 85. philips Structural Heart Disease Interventional Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 86. philips Main Business
Table 87. philips Latest Developments
Table 88. Japen Lifeline Basic Information, Structural Heart Disease Interventional Therapy Manufacturing Base, Sales Area and Its Competitors
Table 89. Japen Lifeline Structural Heart Disease Interventional Therapy Product Portfolios and Specifications
Table 90. Japen Lifeline Structural Heart Disease Interventional Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 91. Japen Lifeline Main Business
Table 92. Japen Lifeline Latest Developments
Table 93. Neovasc Basic Information, Structural Heart Disease Interventional Therapy Manufacturing Base, Sales Area and Its Competitors
Table 94. Neovasc Structural Heart Disease Interventional Therapy Product Portfolios and Specifications
Table 95. Neovasc Structural Heart Disease Interventional Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 96. Neovasc Main Business
Table 97. Neovasc Latest Developments
Table 98. Append Medical Basic Information, Structural Heart Disease Interventional Therapy Manufacturing Base, Sales Area and Its Competitors
Table 99. Append Medical Structural Heart Disease Interventional Therapy Product Portfolios and Specifications
Table 100. Append Medical Structural Heart Disease Interventional Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 101. Append Medical Main Business
Table 102. Append Medical Latest Developments
Table 103. Transverse Medical Basic Information, Structural Heart Disease Interventional Therapy Manufacturing Base, Sales Area and Its Competitors
Table 104. Transverse Medical Structural Heart Disease Interventional Therapy Product Portfolios and Specifications
Table 105. Transverse Medical Structural Heart Disease Interventional Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 106. Transverse Medical Main Business
Table 107. Transverse Medical Latest Developments
Table 108. Cardiomech Basic Information, Structural Heart Disease Interventional Therapy Manufacturing Base, Sales Area and Its Competitors
Table 109. Cardiomech Structural Heart Disease Interventional Therapy Product Portfolios and Specifications
Table 110. Cardiomech Structural Heart Disease Interventional Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 111. Cardiomech Main Business
Table 112. Cardiomech Latest Developments
Table 113. Thubrikar Aortic Valve Inc. Basic Information, Structural Heart Disease Interventional Therapy Manufacturing Base, Sales Area and Its Competitors
Table 114. Thubrikar Aortic Valve Inc. Structural Heart Disease Interventional Therapy Product Portfolios and Specifications
Table 115. Thubrikar Aortic Valve Inc. Structural Heart Disease Interventional Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 116. Thubrikar Aortic Valve Inc. Main Business
Table 117. Thubrikar Aortic Valve Inc. Latest Developments
Table 118. boston scientific Basic Information, Structural Heart Disease Interventional Therapy Manufacturing Base, Sales Area and Its Competitors
Table 119. boston scientific Structural Heart Disease Interventional Therapy Product Portfolios and Specifications
Table 120. boston scientific Structural Heart Disease Interventional Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 121. boston scientific Main Business
Table 122. boston scientific Latest Developments
Table 123. Edwards Lifesciences Corporation Basic Information, Structural Heart Disease Interventional Therapy Manufacturing Base, Sales Area and Its Competitors
Table 124. Edwards Lifesciences Corporation Structural Heart Disease Interventional Therapy Product Portfolios and Specifications
Table 125. Edwards Lifesciences Corporation Structural Heart Disease Interventional Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 126. Edwards Lifesciences Corporation Main Business
Table 127. Edwards Lifesciences Corporation Latest Developments
Table 128. Biomerics Basic Information, Structural Heart Disease Interventional Therapy Manufacturing Base, Sales Area and Its Competitors
Table 129. Biomerics Structural Heart Disease Interventional Therapy Product Portfolios and Specifications
Table 130. Biomerics Structural Heart Disease Interventional Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 131. Biomerics Main Business
Table 132. Biomerics Latest Developments
Table 133. LivaNova PLC Basic Information, Structural Heart Disease Interventional Therapy Manufacturing Base, Sales Area and Its Competitors
Table 134. LivaNova PLC Structural Heart Disease Interventional Therapy Product Portfolios and Specifications
Table 135. LivaNova PLC Structural Heart Disease Interventional Therapy Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2024)
Table 136. LivaNova PLC Main Business
Table 137. LivaNova PLC Latest Developments
List of


Figure 1. Picture of Structural Heart Disease Interventional Therapy
Figure 2. Structural Heart Disease Interventional Therapy Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Structural Heart Disease Interventional Therapy Sales Growth Rate 2019-2030 (K Units)
Figure 7. Global Structural Heart Disease Interventional Therapy Revenue Growth Rate 2019-2030 ($ Millions)
Figure 8. Structural Heart Disease Interventional Therapy Sales by Region (2019, 2023 & 2030) & ($ Millions)
Figure 9. Product Picture of Equipment
Figure 10. Product Picture of Consumables
Figure 11. Global Structural Heart Disease Interventional Therapy Sales Market Share by Type in 2023
Figure 12. Global Structural Heart Disease Interventional Therapy Revenue Market Share by Type (2019-2024)
Figure 13. Structural Heart Disease Interventional Therapy Consumed in Hospital
Figure 14. Global Structural Heart Disease Interventional Therapy Market: Hospital (2019-2024) & (K Units)
Figure 15. Structural Heart Disease Interventional Therapy Consumed in Clinic
Figure 16. Global Structural Heart Disease Interventional Therapy Market: Clinic (2019-2024) & (K Units)
Figure 17. Structural Heart Disease Interventional Therapy Consumed in Others
Figure 18. Global Structural Heart Disease Interventional Therapy Market: Others (2019-2024) & (K Units)
Figure 19. Global Structural Heart Disease Interventional Therapy Sales Market Share by Application (2023)
Figure 20. Global Structural Heart Disease Interventional Therapy Revenue Market Share by Application in 2023
Figure 21. Structural Heart Disease Interventional Therapy Sales Market by Company in 2023 (K Units)
Figure 22. Global Structural Heart Disease Interventional Therapy Sales Market Share by Company in 2023
Figure 23. Structural Heart Disease Interventional Therapy Revenue Market by Company in 2023 ($ Million)
Figure 24. Global Structural Heart Disease Interventional Therapy Revenue Market Share by Company in 2023
Figure 25. Global Structural Heart Disease Interventional Therapy Sales Market Share by Geographic Region (2019-2024)
Figure 26. Global Structural Heart Disease Interventional Therapy Revenue Market Share by Geographic Region in 2023
Figure 27. Americas Structural Heart Disease Interventional Therapy Sales 2019-2024 (K Units)
Figure 28. Americas Structural Heart Disease Interventional Therapy Revenue 2019-2024 ($ Millions)
Figure 29. APAC Structural Heart Disease Interventional Therapy Sales 2019-2024 (K Units)
Figure 30. APAC Structural Heart Disease Interventional Therapy Revenue 2019-2024 ($ Millions)
Figure 31. Europe Structural Heart Disease Interventional Therapy Sales 2019-2024 (K Units)
Figure 32. Europe Structural Heart Disease Interventional Therapy Revenue 2019-2024 ($ Millions)
Figure 33. Middle East & Africa Structural Heart Disease Interventional Therapy Sales 2019-2024 (K Units)
Figure 34. Middle East & Africa Structural Heart Disease Interventional Therapy Revenue 2019-2024 ($ Millions)
Figure 35. Americas Structural Heart Disease Interventional Therapy Sales Market Share by Country in 2023
Figure 36. Americas Structural Heart Disease Interventional Therapy Revenue Market Share by Country in 2023
Figure 37. Americas Structural Heart Disease Interventional Therapy Sales Market Share by Type (2019-2024)
Figure 38. Americas Structural Heart Disease Interventional Therapy Sales Market Share by Application (2019-2024)
Figure 39. United States Structural Heart Disease Interventional Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 40. Canada Structural Heart Disease Interventional Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 41. Mexico Structural Heart Disease Interventional Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 42. Brazil Structural Heart Disease Interventional Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 43. APAC Structural Heart Disease Interventional Therapy Sales Market Share by Region in 2023
Figure 44. APAC Structural Heart Disease Interventional Therapy Revenue Market Share by Regions in 2023
Figure 45. APAC Structural Heart Disease Interventional Therapy Sales Market Share by Type (2019-2024)
Figure 46. APAC Structural Heart Disease Interventional Therapy Sales Market Share by Application (2019-2024)
Figure 47. China Structural Heart Disease Interventional Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 48. Japan Structural Heart Disease Interventional Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 49. South Korea Structural Heart Disease Interventional Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 50. Southeast Asia Structural Heart Disease Interventional Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 51. India Structural Heart Disease Interventional Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 52. Australia Structural Heart Disease Interventional Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 53. China Taiwan Structural Heart Disease Interventional Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 54. Europe Structural Heart Disease Interventional Therapy Sales Market Share by Country in 2023
Figure 55. Europe Structural Heart Disease Interventional Therapy Revenue Market Share by Country in 2023
Figure 56. Europe Structural Heart Disease Interventional Therapy Sales Market Share by Type (2019-2024)
Figure 57. Europe Structural Heart Disease Interventional Therapy Sales Market Share by Application (2019-2024)
Figure 58. Germany Structural Heart Disease Interventional Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 59. France Structural Heart Disease Interventional Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 60. UK Structural Heart Disease Interventional Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 61. Italy Structural Heart Disease Interventional Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 62. Russia Structural Heart Disease Interventional Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 63. Middle East & Africa Structural Heart Disease Interventional Therapy Sales Market Share by Country in 2023
Figure 64. Middle East & Africa Structural Heart Disease Interventional Therapy Revenue Market Share by Country in 2023
Figure 65. Middle East & Africa Structural Heart Disease Interventional Therapy Sales Market Share by Type (2019-2024)
Figure 66. Middle East & Africa Structural Heart Disease Interventional Therapy Sales Market Share by Application (2019-2024)
Figure 67. Egypt Structural Heart Disease Interventional Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 68. South Africa Structural Heart Disease Interventional Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 69. Israel Structural Heart Disease Interventional Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 70. Turkey Structural Heart Disease Interventional Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 71. GCC Country Structural Heart Disease Interventional Therapy Revenue Growth 2019-2024 ($ Millions)
Figure 72. Manufacturing Cost Structure Analysis of Structural Heart Disease Interventional Therapy in 2023
Figure 73. Manufacturing Process Analysis of Structural Heart Disease Interventional Therapy
Figure 74. Industry Chain Structure of Structural Heart Disease Interventional Therapy
Figure 75. Channels of Distribution
Figure 76. Global Structural Heart Disease Interventional Therapy Sales Market Forecast by Region (2025-2030)
Figure 77. Global Structural Heart Disease Interventional Therapy Revenue Market Share Forecast by Region (2025-2030)
Figure 78. Global Structural Heart Disease Interventional Therapy Sales Market Share Forecast by Type (2025-2030)
Figure 79. Global Structural Heart Disease Interventional Therapy Revenue Market Share Forecast by Type (2025-2030)
Figure 80. Global Structural Heart Disease Interventional Therapy Sales Market Share Forecast by Application (2025-2030)
Figure 81. Global Structural Heart Disease Interventional Therapy Revenue Market Share Forecast by Application (2025-2030)

Related Tags

Related Reports

payment cards

One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information

One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information

Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information

All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information

Safe and Secure SSL Encrypted

Quick Contacts

Want to customize this report?

We offer 10% Free Customization at the time of purchase

Get Free Customization

I'm Available

Kavita Mehra

Kavita Mehra

Business Development Manager

Trusted Partners

NONWOVENS_INDUSTRY
FB
issuewire
Financial_Express
logo_yourstory
FB

Budget constraints? Get in touch with us for special pricing

Request Discount

Order Detail

  • Order Placed (09 May, 2026)
  • Notify To Team (09 May, 2026)
  • Report updation (10 May, 2026)
  • Report Quality Check (10 May, 2026)
  • Report Dispatch (11 May, 2026)

  • paypal
  • icici
  • stripe
  • wire-transfer

  • Email
  • Hard Copy

Research Methodology

An Adaptive Approach to Modern-day Research Needs

Get Methodology

Recently Viewed Products

Logo

Global Structural Heart Disease Interventional Therapy Market Growth 2024-2030

ChatGPT Summarize Gemini Summarize Perplexity AI Summarize Grok AI Summarize Copilot Summarize

Contact usWe are friendly and approachable, give us a call.

We uses Cookies

We use cookies to ensure you get the best experience on our website.